Diagnostic and Translational Challenges in Canine Endocrine and Neuroendocrine Neoplasms: A Comparative Pathology Perspective
Veterinary and Comparative Oncology · 18.11.2026
DOI: 10.1111/vco.70130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 18.11.2026. Verfasst von Stefanie Mitze und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Services, The Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, UK. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beryl Evetts and Robert Luff Animal Welfare Trust.
Abstract (Originalsprache)
The recognition and detection of endocrine and neuroendocrine neoplasms (NENs) in dogs and humans is challenging. This is, in part, because some are non‐functional, and where hormone hypersecretion occurs, it can lead to a great variety of clinical syndromes. Additionally, metastatic patterns vary according to the primary anatomical site, and the typically slow growth of many endocrine tumours/NENs may lead to underestimation of biological aggressiveness and misclassification as benign disease. In human medicine, diagnostic evaluation relies on a comprehensive, anatomical site‐specific histopathologic framework, incorporating immunohistochemistry as formalised in the 2025 World Health Organisation classification of endocrine tumours/NENs. In contrast, veterinary diagnostic frameworks for canine endocrine tumours/NENs remain comparatively underdeveloped, with limited standardisation of terminology, grading systems, and validated cut‐off values. This review aims to raise awareness of key diagnostic challenges associated with the most clinically prevalent canine endocrine tumours/NENs: insulinoma, phaeochromocytoma and cortisol‐producing adrenocortical tumours. Emphasis is placed on histopathological characterisation using immunohistochemistry, drawing parallels with established human diagnostic algorithms where appropriate. By synthesising current knowledge from human and canine pathology, this review highlights critical gaps in veterinary diagnostic practice and identifies opportunities for harmonisation of classification strategies. The development of standardised diagnostic guidelines has the potential not only to improve clinical management of affected dogs but also to strengthen the translational value of spontaneous canine endocrine tumours/NENs within the field of comparative oncology and One Medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Science and Services, The Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, UK.
- Department of Pathobiology & Population Sciences, The Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, UK.
- Bukhman Centre for Research Excellence in Type 1 Diabetes, Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, UK.
ORCID-Profile: Stefanie Mitze, Jonathan Williams, Lucy Jane Davison, Dong Xia, Floryne Ottilie Buishand
Förderung
- Beryl Evetts and Robert Luff Animal Welfare Trust
Zitieren
APA
Mitze, S., Williams, J., Davison, L. J., Xia, D., & Buishand, F. O. (2026). Diagnostic and Translational Challenges in Canine Endocrine and Neuroendocrine Neoplasms: A Comparative Pathology Perspective. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.70130
Vancouver
Mitze S, Williams J, Davison LJ, Xia D, Buishand FO. Diagnostic and Translational Challenges in Canine Endocrine and Neuroendocrine Neoplasms: A Comparative Pathology Perspective. Veterinary and Comparative Oncology. 2026. doi:10.1111/vco.70130
BibTeX
@article{Mitze2026,
author = {Mitze, Stefanie and Williams, Jonathan and Davison, Lucy Jane and Xia, Dong and Buishand, Floryne Ottilie},
title = {Diagnostic and Translational Challenges in Canine Endocrine and Neuroendocrine Neoplasms: A Comparative Pathology Perspective},
journal = {Veterinary and Comparative Oncology},
year = {2026},
doi = {10.1111/vco.70130}
}
EUVIMED